Delayed chylomicron remnant clearance in subjects with heterozygous familial hypercholesterolaemia

Journal of Internal Medicine

Volumn 244, Issue 4, 1998, Pages 299-307

  Castro Cabezas, M ^a   De Bruin, T W A ^b   Westerveld, H E ^a   Meijer, E ^a   Erkelens, D W ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Atherosclerosis; Chylomicrons; Familial hypercholesterolaemia (FH); Remnant receptor and triglycerides

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN E; CHYLOMICRON; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; RETINOL PALMITATE; TRIACYLGLYCEROL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HETEROZYGOTE; HUMAN; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LOADING TEST; MALE; PLASMA CLEARANCE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; CASE-CONTROL STUDIES; CHYLOMICRONS; FASTING; FEMALE; HETEROZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPIDS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; RECEPTORS, LDL; REGRESSION ANALYSIS; TIME FACTORS; TRIGLYCERIDES;

EID: 0031683495     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1998.00367.x     Document Type: Article

References (47)

1. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation 1979; 60: 473-85.
2. Simons LA, Dwyer T, Simons J, Bernstein L, Mock P, Poonia NS et al. Chylomicrons and chylomicron remnants ill coronary artery disease: a case-control study. Atherosclerosis 1987; 65: 181-89.
3. Patsch JR, Miesenbock G, Hopferwieser T, Muhlberger V, Knapp E, Dunn JK et al. Relation to triglyceride metabolism and coronary artery disease: studies in the postprandial state. Arterioscl Thromb 1992; 12: 1336-45.
4. Haffner SM, Kushwaha RS, Hazzard WR. Metabolism of chylomicrons in subjects with dysbetalipoproteinaemia (type III hyperlipoproteinaemia). Eur J Clin Invest 1989; 19: 486-90.
5. Mahley RW, Hui DY, Innerarity TL, Beisiegel U. Chylomicron remnant metabolism: role of hepatic lipoprotein receptors in mediating uptake. Arteriosclerosis 1989; 19 (Suppl.); 114-18.
6. Hussain MM, Maxfield FR, Mâs-Olivas J, Tabas I, Ji Z-S, Innerarity TL, Mahley RW. Clearance of chylomicron remnants by the low density lipoprotein receptor-related protein/α2-macroglobulin receptor. J Biol Chem 1991; 266: 13936-40.
7. Luoma J, Hiltunen T, Särkioja T, Moestrup SK, Gliemann J, Kodama T, et al. Expression of α2-macroglobulin receptor/low density lipoprotein receptor-related protein and scavenger receptor in human atherosclerotic lesions. J Clin Invest 1994; 93: 2014-21.
8. 2-macroglobulin-recognition site. Biochem J 1991; 279: 863-70.
9. Windler E, Greeve J, Levkau B, Kolb-Bachofen V, Daerr W, Greten H. The human asialoglycoprotein receptor is a possible binding site for low-density lipoproteins and chylomicron remnants. Biochem J 1991; 276: 79-87.
10. Mann CJ, Khallou J, Chevreuil O, Troussard A, Guermant LM, Launay K et al. Mechanism of activation and functional significance of the lipolysis-stimulated receptor: evidence for a role as chylomicron remnant receptor. Biochem J 1995; 34: 10421-31.
11. Jäckle S, Rinninger F, Greeve J, Greten H, Windler E. Regulation of the hepatic removal of chylomicron remnants and β-very low density lipoproteins in the rat. J Lipid Res 1992; 33: 419-29.
12. Borensztajn J, Kotlar TJ, Chang S. Apoprotein-independent binding of chylomicron remnants to rat liver membranes. Biochem J 1991; 279: 769-73.
13. Niemeier A, Gåfvels M, Heeren J, Angelin B, Beisiegel U. VLDL receptor mediates the uptake of human chylomicron remnants in vitro. J Lipid Res 1996; 37: 1753-42.
14. Takahashi S, Kawarabayasi Y, Nakai T, Yamamoto T. Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity. Proc Natl Acad Sci USA 1992; 89: 9252-56.
15. Kowal RC, Herz J, Goldstein JL, Esser V, Brown MS. Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins. Proc Natl Acad Sci USA 1989; 86: 5810-14.
16. Hamilton RL, Wong JS, Guo LSS, Krisans S, Havel RJ. Apolipoprotein E localization in rat hepatocytes by immunogold labelling of cryothin sections. J Lipid Res 1990; 31: 1589-603.
17. Hui DY, Innerarity TL, Milne RW, Marcel Y, Mahley RW. Binding of chylomicron remnants and β-very-low-density lipoproteins to hepatic and extrahepatic lipoprotein receptors. A process independent of apolipoprotein B48. J Biol Chem 1984; 259: 15060-68.
18. Innerarity TL, Pitas RE, Mahley RW. Binding of arginine-rich (E) apoprotein after recombination with phospholipid vesicles to the low density lipoprotein receptor of fibroblasts. J Biol Chem 1979; 254: 4186-90.
19. Kowal RC, Herz J, Weisgraber KH, Mahley RW, Brown MS, Goldstein JL. Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J Biol Chem 1990; 265: 10771-79.
20. Mahley RW, Innerarity TL, Rall SC, Weisgraber KH. Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res 1984; 25: 1277-94.
21. Willnow TE, Sheng Z, Ishibashi S, Herz J. Inhibition of hepatic chylomicron remnant uptake by gene transfer of a receptor antagonist. Science 1994; 264: 1471-74.
22. Beisiegel U, Weber W, Bengtsson-Olivecrona G. Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein-receptor related protein. Proc Natl Acad Sci USA 1991; 88: 8342-46.
23. Skottova N, Savonen R, Lookene A, Hultin M, Olivecrona G. Lipoprotein lipase enhances removal of chylomicrons and chylomicron remnants by the perfused rat liver. J Lipid Res 1995; 36: 1334-44.
24. Krapp A, Ahle S, Kersting S, Hua Y, Kneser K, Nielsen M et al. Hepatic lipase mediates the uptake of chylomicrons and β-VLDL into cells via the LDL receptor-related protein (LRP). J Lipid Res 1996; 37: 926-36.
25. Hussain MM, Innerarity TL, Brecht WJ, Mahley RW. Chylomicron metabolism in normal, cholesterol-fed, and Watanabe heritable hyperlipidaemic rabbits. Saturation of the sequestration step of the remnant clearance pathway. J Biol Chem 1995; 270: 8578-87.
26. Skrede B, Blomhoff R, Maelandsmo GM, Ose L, Myklebost O, Norum KR. Uptake of chylomicron remnant retinyl esters in human leukocytes in vivo. Eur J Clin Invest 1992; 22: 229-34.
27. Eriksson M, Angelin G, Henriksson P, Ericsson S, Vitols S, Berglund L. Metabolism of lipoprotein remnants in humans. Studies during intestinal infusion of fat and cholesterol in subjects with varying expression of the low density lipoprotein receptor. Arterioscler Thromb 1991; 11: 827-37.
28. Choi SY, Fong LG, Kirven MJ, Cooper AD. Use of an anti-low density lipoprotein receptor antibody to quantify the role of the LDL receptor in the removal of chylomicron remnants in the mouse in vivo. J Clin Invest 1991; 88: 173-181.
29. Rubinsztein DC, Cohen JC, Berger M, van der Westhuyzen DR, Coetzee GA, Gevers W. Chylomicron remnant clearance from the plasma is normal in familial hypercholesterolaemic homozygotes with defined receptor defects. J Clin Invest 1990; 86: 1306-12.
30. Bowler A, Redgrave TG, Mamo JCL. Chylomicron-remnant clearance in homozygote and heterozygote Watanabe-heritable-hyperlipidaemic rabbits is defective. Lack of evidence for an independent chylomicron-remnant receptor. Biochem J 1991; 276: 381-86.
31. Lechleitner M, Hoppichler F, Föger B, Patsch JR. Low-density lipoproteins of the postprandial state induce cellular cholesteryl ester accumulation in macrophages. Arterioscl Thromb 1994; 14: 1799-807.
32. th ed. New York, USA: McGraw-Hill, 1983: 672-712.
33. Dallinga-Thie GM, van Linde-Sibenius T, Rip M, Kock LAW, de Bruin TWA. Apolipoprotein E2/E3/E4 genotyping with agarose gels. Clin Chem 1995; 41: 73-75.
34. De Bruin TWA, Brouwer CB, Gimpel JA, Erkelens DW. Postprandial decrease in HDL cholesterol and HDL-associated apolipoprotein A-1 in normal subjects in relation to triglyceride metabolism. Am J Physiol 1991; 260: E492-E498.
35. Castro Cabezas M, de Bruin TWA, Kock LAW, Kortlandt W, van Linde-Sibenius Trip M, Jansen H, Erkelens DW. Simvastatin improves chylomicron remnant removal in familial combined hyperlipidaemia without changing chylomicron conversion. Metabolism 1993; 42: 497-503.
36. Castro Cabezas M, de Bruin TWA, Jansen H, Kock LAW, Kortlandt W, Erkelens DW. Impaired chylomicron remnant clearance in familial combined hyperlipidaemia. Arterioscl Thromb 1993; 13: 804-14.
37. Weintraub MS, Eisenberg S, Breslow JL. Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III, and type IV hyperlipoproteinaemic individuals: effects of treatment with cholestyramine and gemfibrozil. J Clin Invest 1987; 79: 1110-19.
38. Brunzell JD, Hazzard WR, Porte DJ, Bierman EL. Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man. J Clin Invest 1973; 52: 1578-85.
39. Cianflone K, Bilodeau M, Davignon J, Sniderman AD. Modulation of chylomicron remnant metabolism by an hepatic hydroxymethylglutaryl coenzyme A reductase inhibitor. Metabolism 1990; 39: 274-80.
40. Reitsma JB, Castro Cabezas M, de Bruin TWA, Erkelens DW. Relationship between improved postprandial lipaemia and low-density lipoprotein metabolism during treatment with tetrahydrolipstatin, a pancreatic lipase inhibitor. Metabolism 1994; 43: 293-98.
41. Gylling H, Relas H, Miettinen TA. Postprandial vitamin A and squalene clearances and cholesterol synthesis off and on lovastatin treatment in type III hyperlipoproteinaemia. Atherosclerosis 1995; 115: 17-26.
42. Cummings MH, Watt GF, Umpleby M, Hennessy TR, Quiney JR, Sönksen PH. Increased hepatic secretion of very-low-density-lipoprotein B-100 in heterozygous familial hypercholesterolaemia: a stable isotope study. Atherosclerosis 1995; 113: 79-89.
43. Demacker PNM, Van Heijst PJ, Stalenhoef AFH. A study of the chylomicron metabolism in WHHL rabbits after fat loading. Discrepancy between results based on measurement of apoprotein B-48 or retinyl palmitate. Biochem J 1992; 285: 641-46.
44. Ginsberg HN, Karmally W, Siddiqui M, Holleran S, Tall AR, Rumsey SC et al. A dose-response study of the effects of dietary cholesterol on fasting and postprandial lipid and lipoprotein metabolism in healthy young men. Arterioscl Thrombosis 1994; 14: 576-86.
45. O'Connor P, Feely J, Shepherd J. Lipid lowering drugs. Br Med J 1990; 300: 667-72.
46. Mamo JCL, Elsegood C, Umeda Y, Hirano T, Redgrave TG. The effect of probucol on plasma clearance and organ uptake of chylomicrons and very low density lipoproteins in normal and diabetic rats. Arterioscl Thromb 1993; 13: 231-39.
47. Rensen PCN, Herijgers N, Netscher MH, Meskers SCJ, Van Eck M, Van Berkel ThJC. Particle size determines the specificity of apolipoprotein E-containing triglyceride-rich emulsions for the LDL receptor versus hepatic remnant receptor in vivo. J Lipid Res 1997; 38: 1070-84.